title: Editorial comment from Dr Murtola to reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
authors.affiliation: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. teemu.murtola@uta.fi.
authors.forename: Teemu J
authors.initials: TJ
authors.lastname: Murtola
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D009281:Naphthalenes; D010879:Piperazines; D016212:Transforming Growth Factor beta; C064357:naftopidil